Febit Restructures to Concentrate on miRNA Biomarkers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Febit today announced it is restructuring its business "as a consequence of its strategic focus on blood-based microRNA biomarker discovery."

As a result, CEO and President Cord Staehler has resigned and joined Siemens Healthcare. Hartmut Voss has joined the company as co-CEO. Jochen Kohlhaas is the other co-CEO and will continue as the company's chief financial officer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.